Abstract
BACKGROUND Pancreatic cancer (PaC) has poor (10%) 5-year overall survival, largely due to predominant late-stage diagnosis. Patients with new-onset diabetes (NOD) are at a six-to eightfold increased risk for PaC. We developed a pancreatic cancer detection test for the use in a clinical setting that employs a logistic regression model based on 5-hydroxymethylcytosine (5hmC) profiling of cell-free DNA (cfDNA).
METHODS cfDNA was isolated from plasma from 89 subjects with PaC and 596 case-control non-cancer subjects, and 5hmC libraries were generated and sequenced. These data coupled with machine-learning, were used to generate a predictive model for PaC detection, which was independently validated on 79 subjects with PaC, 163 non-cancer subjects, and 506 patients with non-PaC cancers.
RESULTS The area under the receiver operating characteristic curve for PaC classification was 0.93 across the training data. Training sensitivity was 58.4% (95% confidence interval [CI]: 47.5– 68.6) after setting a classification probability threshold that resulted in 98% (95% CI: 96.5–99) specificity. The independent validation dataset sensitivity and specificity were 51.9% (95% CI: 40.4–63.3) and 100.0% (95% CI: 97.8–100.0), respectively. Early-stage (stage 1 and 2) PaC detection was 47.6% (95% CI: 23%–58%) and 39.4% (95% CI: 32%–64%) in the training and independent validation datasets, respectively. Sensitivity and specificity in NOD patients were 55.2% [95% CI: 35.7–73.6] and 98.4% [95% CI: 91.3–100.0], respectively. The PaC signal was identified in intraductal papillary mucinous neoplasm (64%), pancreatitis (56%), and non-PaC cancers (17%).
CONCLUSIONS The pancreatic cancer detection assay showed robust performance in the tested cohorts and carries the promise of becoming an essential clinical tool to enable early detection in high-risk NOD patients.
Competing Interest Statement
All authors are full-time employees and shareholders of Bluestar Genomics and have declared no other conflicts of interest.
Funding Statement
This work was supported by Bluestar Genomics. Bluestar Genomics was involved in the study design, study execution, analysis and interpretation (no grant number).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sterling ; WIRB. The study protocol submission, IRB approval and specimen handling across all sites were managed by CROs who provided clinical research specimen handling services.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant Support: This work was supported by Bluestar Genomics. Bluestar Genomics was involved in the study’ s design, study execution, analysis and interpretation (no grant number).
Disclosures: All authors are full-time employees and shareholders of Bluestar Genomics and have declared no other conflicts of interest.
Writing Assistance: Medical writing support was provided by Tracy McNally and Ify Sargeant on behalf of Twist Medical and funded by Bluestar Genomics.
Writing Assistance: list names and funding source for individuals who provided writing assistance.
Data Availability
The Fastq files can be made available upon written request for submission to the study institutional review boards at the participating sites.
Abbreviations used in this paper
- 5hmC
- 5-hydroxymethylcytosine
- auROC
- area under the receiver operating characteristic curve
- CA19-9
- carbohydrate antigen 19-9
- cfDNA
- cell-free DNA
- CI
- confidence interval
- CPM
- counts per million
- CT
- computerized tomography
- EUS
- endoscopic ultrasound
- IPMN
- intraductal papillary mucinous neoplasm
- IRB
- Institutional Review Board
- KRAS
- Kirsten rat sarcoma virus
- MSigDB
- Molecular Signatures Database
- NA
- not available
- NES
- normalized enrichment score
- NOD
- new-onset diabetes
- OOPC
- out-of- panel cancer
- PaC
- pancreatic cancer
- PDAC
- pancreatic ductal adenocarcinoma
- QC
- quality control
- yo
- year old
